

Is it COVID-19, Flu, RSV, or something else?



Respiratory tests can help you make a precise diagnosis

SARS-CoV-2 (COVID-19), influenza A or B (flu), RSV, and other respiratory infections can present with similar symptoms such as fever, cough, and shortness of breath.

That's why it's important to consider testing for each of these contagious illnesses at the same time—especially for children, older adults, pregnant women, and people with underlying conditions or compromised immune systems.

Knowing which infection—or infections—are causing your patient's symptoms will help you make the best treatment decisions.

Whether caused by COVID-19, influenza, or another respiratory illness, the symptoms can be very similar¹:

- Fever or feeling feverish/chills
- Cough
- Shortness of breath or difficulty breathing
- Fatigue (tiredness)
- Sore throat
- Runny or stuffy nose
- Muscle pain or body aches
- Headache
- Some people may have vomiting and diarrhea, though this is more common in children than adults

Combination testing options with Sonora Quest

Our testing options use a single specimen to co-test for common respiratory pathogens, which help expedite diagnosis so you can develop an appropriate treatment/care plan.

Now available at Sonora Quest Patient Service Centers

SARS-CoV-2 RNA (COVID-19) and all other combination testing is now available for nasal or nasopharyngeal sample collection at one of nearly 60 Sonora Quest Patient Service Centers for patients with mild symptoms.

Clinicians are encouraged to consider testing for other viral causes of respiratory illness if activity is present in their local area.²



For more information contact your
Sonora Quest Account Manager

Identifying the source of infection is the first step in managing patient care

Sonora Quest offers the convenience of co-testing for influenza A and B and RSV in conjunction with testing for SARS-CoV-2.

Molecular Offerings & Panels for Respiratory Pathogen Testing	Test Code	CPT Code(s)	Sample
SARS-CoV-2 RNA (COVID-19), Qualitative NAAT	907080	87635	Nasopharyngeal; Nasal
SARS-CoV-2 (COVID-19) and Influenza A/B, Qualitative, NAAT	907258	87636	Nasopharyngeal; Nasal
SARS-CoV-2 RNA, Influenza A/B, and RSV RNA, Qualitative NAAT	804283	87635, 87631	Nasopharyngeal

Molecular Respiratory Pathogen Tests & Panels (Non-COVID)	Test Code	CPT Code(s)	Sample
Influenza A/B RNA, Qualitative Real-Time PCR	903105	87502	Nasopharyngeal; Throat
Influenza A/B and RSV, Qualitative, Real-Time PCR	906336	87631	Nasopharyngeal

Supply information

Anterior Nares (Nasal)/Oropharyngeal (Throat) (Large Swab): Viral Transport Media (VTM) or equivalent Universal Transport Media (UTM) (Supply #20011)

Nasopharyngeal: Viral Transport Media (VTM) or equivalent Universal Transport Media (UTM) (Supply #20012)

Count on Sonora Quest: the right test for the right patient for faster diagnosis and treatment.

- The cobas SARS-CoV-2 & Influenza A/B, Aptima SARS-CoV-2 assay, and PerkinElmer New Coronavirus Nucleic Acid Detection Kit have not been FDA cleared or approved.
- The Roche® cobas SARS-CoV-2 & Influenza A/B tests has been authorized only for the detection of RNA from SARS-CoV-2 virus, Influenza A virus, and Influenza B virus and not any other viruses or pathogens.
- The cobas SARS-CoV-2, Aptima SARS-CoV-2 assay, and PerkinElmer tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
- The cobas SARS-CoV-2 & Influenza A/B test is only authorized for the duration of the declaration that circumstances exist justifying the authorized of the emergency use of in vitro diagnostics for detection and differentiation of SARS-CoV-2 virus, Influenza A, and Influenza B under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb- 3(b)(1), unless the authorized is terminated or revoked sooner.
- The tests have been authorized by the FDA under an EUA for use by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, to perform moderate and high complexity tests.

References:

1. CDC. Similarities and differences between flu and COVID-19. Updated June 7, 2021. Accessed September 1, 2021. <https://www.cdc.gov/flu/symptoms/flu-vs-covid19.htm>
2. CDC. Interim clinical guidance for patients with confirmed coronavirus disease (COVID-19). Updated February 16, 2021. <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html>

SonoraQuest.com

Sonora Quest Laboratories, any associated logos, and all associated Sonora Quest Laboratories registered or unregistered trademarks are the property of Sonora Quest Laboratories. All third-party marks—® and ™—are the property of their respective owners. © 2023 Sonora Quest Laboratories. All rights reserved. 11/2023



A Subsidiary of Laboratory Sciences of Arizona